Lilly says manufacturing, compliance heads to retire
Reuters
Published Mar 09, 2021 12:28PM ET
(Reuters) - Drugmaker Eli Lilly (NYSE:LLY) and Co said on Tuesday the chiefs of its manufacturing division and the ethics and compliance department will step down from their roles in the coming months.
Myles O'Neill, senior vice president and president of Lilly's manufacturing operations, will retire in early May, after nearly two decades with the company, Lilly said.
O'Neill, 62, will be replaced by Edgardo Hernandez, who is currently senior vice president of the drugmaker's global injectible drug product and device manufacturing division.
The drugmaker also said Chief Ethics and Compliance Officer Melissa Barnes will retire in June.
Barnes, 52, has been with the company for 26 years and will be replaced by Lilly Deputy General Counsel Alonzo Weems.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.